Can Stem Cell Therapy Slow GA? - Takeaways - MDSpire

Can Stem Cell Therapy Slow GA?

Phase 1b data for ASP7317, presented at ASRS, showed a favorable safety profile, encouraging visual acuity findings, and stabilization of geographic atrophy in patients with advanced disease.

  • By

  • VIVIENNE HAU, MD, PHD

  • July 15, 2026

  • 3 min

Share

  • 1

    The Phase 1b trial of ASP7317 demonstrated a favorable safety profile with no significant adverse effects reported.

  • 2

    Best-corrected visual acuity improved in small and medium cohorts over 52 weeks compared to the fellow eye.

  • 3

    Geographic atrophy area showed stabilization over time during the study.

  • 4

    Most patients reported that their vision was either the same or improved according to the Patient Global Impression of Change questionnaire.

  • 5

    ASP7317 is a human stem cell-derived retinal pigment epithelial cell therapy for advanced geographic atrophy.

Original Source(s)

Can Stem Cell Therapy Slow GA?

  • by VIVIENNE HAU, MD, PHD

  • July 15, 2026

Related Content

Longitudinal assessment of intraocular pressure in the 5xFAD mouse model of Alzheimer's disease

Optical coherence tomography acquisition efficiency: comparison of Heidelberg spectralis OCT2 module & Zeiss Cirrus HD-OCT model 6000

SGLT2 inhibitors and diabetic retinopathy progression: evidence from a retrospective cohort study and Mendelian randomization analysis